The purpose of the WELL study is to examine how consuming dietary oils in foods like spreads, bread, cookies, muffins, and brownies everyday influences liver fat.
The study will measure liver fat using and MRI before and after consuming 3 of the study foods per day for 16 weeks. The study will also examine how consuming the study foods each day influences fat in the abdomen and in the blood. The total study duration is 18 weeks.
- Ages 25-80
- Have nonalcoholic fatty liver disease or something similar
Exclusion Criteria Include
- Unable to have an MRI scan
The purpose of this study is to learn about sleep and blood sugar (glucose) levels in people living with Alzheimer’s disease (AD). Another purpose of the study is to see how people with AD and their caregivers/family members feel about wearing small devices to measure sleep and blood sugar.
The duration of this study is 10 days.
- 60 years or older, with Alzheimer’s disease,
- Has a caregiver 18 years or older,
- Willing to wear a watch-like device,
- Willing to wear a small sensor on the skin
The purpose of this study is to lower the rate of type 2 diabetes in rural Appalachia youth due to obesity and/or being overweight. Our long-term goal is to improve the health of underserved, high-risk youth.
This study will test the effectiveness of the Mentored Planning to be Active + Family on physical activity outcomes and health outcomes among rural Appalachian middle school aged youth suffering from either overweight or obesity.
We have local high school-aged teen mentors work closely with middle school youth to increase social support, self-efficacy, and self-regulation skills to sustain physical activity and improve health before the children enter high school.
The peer mentoring is followed by a 6-month family reinforcement program.
Some parents will provide child assessment data of perceived child physical activity behaviors and child health.
- Child has access to a computer or tablet device at home for virtual mentoring sessions/meetings
- Child suffers from overweight or obesity - does not need to be under the care of a health care professional for this condition
- Child and Parent able to participate read English at a 4th grade level.
- Family not expected to move from rural Appalachia within the 18 months.
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment intrahepatic cholestasis of pregnancy (ICP).
Depending upon how many weeks pregnant you are when you are screened at the first study visit, study participation could last up to 27 weeks
• Females aged 18 to 45 years old
• Viable pregnancy of 20 weeks 0 days above
• Diagnosis of intrahepatic cholestasis of pregnancy (ICP)
• Willing and able to not use of any of the following for the duration of the study: statins, rifampin, bile acid sequestrants (e.g., cholestyramine), peroxisome proliferator-activated receptor (PPAR) agonists/fibrate drugs (e.g., fenofibrate, bezafibrate), S-adenosyl methionine.
• Presence of triplets or higher multiple gestation
• Alcohol use disorder or substance abuse within 12 months
• Known diagnosis of HIV infection or HIV antibody positivity
Exclusion Criteria varies, please contact Study Coordinator for more information.
The purpose of this study is to improve hemoglobin A1c levels in patients with type 2 diabetes experiencing food insecurity.
The study will examine the effects of a produce referral program alone and in combination with other interventions. Our research is designed to develop a deeper understanding of how to provide patients with type 2 diabetes that are experiencing food insecurity with the resources, skills, and education to manage their health and social needs.
- Age 18 years and older
- Type 2 diabetes based on American Diabetes Association Criteria
- Hemoglobin A1c level > 7.5%
- Worried about running out of food before you have money to buy more
The purpose of this study is to evaluate whether group-art sessions can reduce stress, improve sleep quality, improve quality of life and decrease severity of digestive symptoms in participants who suffer from chronic digestive issues. Participants will meet virtually once per week for 1.5 hour sessions, via Zoom, and will be provided with art supplies.
The start date will be determined by the date the 1st session starts for a given group. Thus participants can be in the study for up to 14 weeks.
• Male or females aged 18 years or older
• Suffer from Chronic Digestive Symptoms
• Willing to meet virtually once per week for 1.5 hour group sessions
The purpose of this research study is to see if practicing mindful breathing daily can reduce stress, improve sleep
and possibly improve symptoms in patients with Gastroparesis.
Gastroparesis is a condition characterized by symptoms such as nausea, vomiting, feeling excessively full after eating a little bit, bloating and abdominal pain. One or more of these symptoms can be present in a given patient.
Your participation throughout the study will last 6 weeks.
• At least 18 years of age
• Able to read and understand English
• Has symptoms of gastroparesis for at least 6 months (gastric emptying study is NOT required for inclusion)
The purpose of this research study is to better understand the role of fat tissue, how cells in fat tissue communicate, and determine what signals specific cells use to cause inflammation and insulin resistance during weight gain. This may help researchers better understand the process that happens in Type 2 Diabetes.
As a result, through the course of six--nine weeks, participants will be asked to gain at least 10% of their starting body weight. A dietitian will meet with participants to give advice to help with meeting the study weight gain goals, as well as provide additional meal vouchers and supplemental shakes as needed. Following the study, participants will receive guidance how to lose the weight they've gained if they would like to do that.
You may be eligible if you:
- Are 18-60 years of age
- Are lean; Have a BMI 18-24.9 kg/m2 (*see link below for calculating your BMI --Body Mass Index)
- Have healthy levels of cholesterol and triglycerides (These will be tested at screening)
- Are a non-smoker
- Are non-diabetic
- Are free of chronic illness
- Are not pregnant or breastfeeding
*If you want to calculate your BMI https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/english_bmi_c…
- Fasting triglycerides > 150 mg/dL or nonfasting triglycerides ˃ 250 mg/dl
- LDL-Cholesterol level > 150 mg/dL,
- Presence of significant anemia (hemoglobin <10.0 gm/dL),
- Currently or planning to take blood thinners ,
- Current smokers
- Have taken steroids or anti-inflammatory meds for >6 months in the last 6 months
- >10% body weight loss within 3 months of enrollment
*Other exclusions may apply
This study is done for researchers to understand pancreatitis and learn how the disease progresses naturally over time.
From the results of this study, researchers hope to develop some lab tests to support early diagnosis of chronic pancreatitis and to also discover any genetic factors that may affect your chances of developing chronic pancreatitis. The results of this study may also provide information that will open opportunities for new drug discovery.
• You have a history of acute or chronic pancreatitis OR
• You have experienced pain in your abdomen that a doctor has suggested could be due to pancreatitis
• You are between the ages of 18 and 75
The purpose of this study is to learn if a study drug called NI-03 (also known as Camostat) can help people with chronic pancreatitis. We want to find out what effects, good or bad, the study drug has on the disease. It has been approved in Japan and has been available by prescription for the treatment of the acute pain associated with chronic pancreatitis. The study drug will not be approved for sale in the United States until tests from studies like this one show that it is safe and effective.
-You are between the ages of 18-80
-You have a diagnosis of chronic pancreatitis
-For males: documented surgical sterilization, sexual abstinence, or agreed upon means of contraception from screening until 28 days after final dose of study medication is required
-For females: documented surgical sterilization, sexual abstinence, postmenopausal status for at least 1 year, or agreed upon means of contraception from screening until 28 days after final dose of study medication is required